Switzerland· 68026001
Veklury, Pulver für Konzentrat zur Herstellung einer Infusionslösung
A remdesivir product containing remdesivirum, registered in Switzerland by Gilead Sciences Switzerland Sàrl and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Remdesivir is registered in 14 of 19 countries.
Countries holding a registration under ATC J05AB16 (remdesivir), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Remdesivir · ATC J05AB16
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of remdesivir costs, country by country.
Normalised to the WHO defined daily dose (0.12 g), so markets compare like for like.
- Switzerland: $622.55 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Remdesivir · price per daily dose (0.12 g)
USD · FX 28 Sept 2026
- CH Switzerland$622.55
The record
At a glance
Swissmedic (Switzerland)- Active substance
- remdesivirum
- Manufacturer
- Gilead Sciences Switzerland Sàrl
- Country
- Switzerland (CH)
- ATC code
- J05AB16
- ATC class
- Remdesivir
- Defined daily dose
- 0.12 g, P
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680680260012Durchstf 1 StkCHF 430.25
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
252 interactions on record for remdesivir.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Remdesivir · interactions on record
252 records
- 2 severe
- 250 moderate
Most severe, free to view
- ClotrimazoleA01AB18moderate
- Chenodeoxycholic acidA05AA01moderate
- NeomycinA07AA01moderate
- StreptomycinA07AA04moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Remdesivir in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomRemdesivir 100mg powder for concentrate for solution for infusion vialsGilead Sciences Ltd
- BelgiumVeklury 100 mgGilead Sciences Ireland UC
- SpainVEKLURY 100 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONGilead Sciences Ireland Unlimited Company
- FinlandVekluryGilead Sciences Ireland UC
- SwedenVeklury 100 mg Koncentrat till infusionsvätska, lösningGilead Sciences Ireland UC
- United StatesVekluryGilead Sciences, Inc.
- CanadaVEKLURYGILEAD SCIENCES CANADA INC
- IrelandVeklury 100 mg powder for concentrate for solution for infusionGilead Sciences Ireland UC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Veklury
- Liechtenstein · Veklury
- Norway · Veklury
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ed7088af-0763-42b3-b92a-c224ddfd5c80 GET /v1/drugs/ed7088af-0763-42b3-b92a-c224ddfd5c80?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "remdesivirum 100 mg",
"valid_from": "2023-12-01",
"limitations": "[{\"description\":\"VEKLURY als antivirale Monotherapie wird bei einer Behandlung einer bestätigten Covid-19 Infektion (Symptomatik und positiver Erregernachweis Antigen/PCR) in folgenden Fällen vergütet:<br>\\n<br>\\n•\\tErwachsenen und pädiatrischen Patienten (im Alter von mindestens 4 Wochen und mit einem Körpergewicht von mindestens 3 kg) mit einer Pneumonie, die eine zusätzliche Sauerstoffzufuhr erfordert (Low- oder High-Flow-Sauerstoff oder andere nicht-invasive Beatmung zu Beginn der Behandlung)<br>\\n•\\tzur Frühbehandlung (innerhalb von 5 Tagen nach Symptombeginn, ausser bei immunsupprimierten Personen) bei Erwachsenen und pädiatrischen Patienten (mit einem Körpergewicht von mindestens 40 kg), die keine zusätzliche Sauerstoffzufuhr oder Hospitalisierung aufgrund von COVID-19 benötigen und bei welchen gemäss der aktuell gültigen Richtlinie der Schweizerischen Gesellschaft für Infektiologie (SSI) (https://www.sginf.ch/guidelines/guidelines-overview.html) ein erhöhtes Risiko für einen schweren COVID-19-Verlauf besteht.<br>\\n<br>\\nFür die frühzeitige ambulante Behandlung von Hochrisikopatienten, die keine zusätzliche Sauerstoffzufuhr oder Hospitalisierung aufgrund von COVID-19 benötigen, wird für eine Erkrankung maximal eine Dosierung von 400mg während 3 Tagen vergütet (Tag 1: 200mg, Tag 2: 100mg: Tag 3: 100mg).<br>\\n<br>\\nDie ambulante Behandlung muss durch entsprechend spezialisierte Zentren oder Universitätsspitäler (https://www.bag.admin.ch/bag/de/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/Arzneimittel/Referenzdokumente-zur-Spezialitaetenliste.html) eingeleitet werden.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21439.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2024-12-01\",\"validTo\":\"2026-12-31\"}]",
"galenic_form": "Trockensub 100 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2022-09-01",
"self_retention_pct": 10
}See everything about remdesivir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.